Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1786)
  2. Journal Article (1579)
  3. Review (119)
  4. Research Letter (54)
  5. Editorial (46)
  6. Book Section (39)
  7. Guidelines (19)
  8. Conference Paper (18)
  9. Correspondence (12)
  10. Miscellaneous (2)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3675)
  2. Department of Medicine (3644)
  3. Hematologic Malignancies, Division of (3640)
  4. GSK Faculty (1773)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1369)
  6. Executive Committee, Center for Hematologic Malignancies (965)

More Groups

People
  1. Ross Levine (782)
  2. Martin Tallman (651)
  3. David Scheinberg (499)
  4. Jae Park (370)
  5. Eytan Stein (361)
  6. Raajit Rampal (347)

More People

Years
  1. 2025 (61)
  2. 2024 (193)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1249)
  2. Journal of Clinical Oncology (215)
  3. Clinical Lymphoma, Myeloma and Leukemia (116)
  4. Leukemia (109)
  5. Haematologica (106)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1338)
  2. Nature Publishing Group (319)
  3. Elsevier Inc. (256)
  4. American Association for Cancer Research (233)
  5. American Society of Clinical Oncology (227)
  6. Ferrata Storti Foundation (106)

More Publishers

Results (3675)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
    Journal Article

    Valtis, Y. K.; Devlin, S.; Shouval, R.; Rejeski, K.; Corona, M.; De Abia, A. L.; Rivas-Delgado, A.; Luttwak, E.; Cassanello, G.; Landego, I.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • A multi-site break through cancer trial: Phase II study investigating dual inhibition of BCL2 and menin in AML MRD using the combination of venetoclax and revumenib (trial in progress)
    Meeting Abstract

    Issa, G. C.; Ambinder, A. J.; Xiao, W.; Manalis, S.; Shalek, A. K.; Gondek, L. P.; Kentsis, A.; Short, N. J.; Daver, N.; Ning, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Results from the Great Britain AML real world evidence (ARC) initiative - A centre-based chart review study to assess treatment outcomes of venetoclax for the treatment of acute myeloid leukemia
    Meeting Abstract

    O'Nions, J.; Errico, G.; Floro, L.; Murthy, V.; Sweeney, C.; Kaur, H.; Mohite, U.; Ayto, R.; Alvares, C.; Goldberg, A. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Optimizing therapeutic outcome of CD19(T2)28z1XX chimeric antigen receptor (CAR) T in adult patients with large B-cell lymphoma through a quantitative medicine approach
    Meeting Abstract

    Dey, A.; Li, J.; Park, J. H.; Sellner, L.; Sundaresan, V.; Palomba, M. L.; Mansilla-Soto, J.; Senechal, B.; Wang, X.; Sikder, D. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 2B, open-label multicenter study of tebapivat (AG-946), a potent pyruvate kinase activator, in patients
    Meeting Abstract

    Zeidan, A. M.; Sekeres, M. A.; Al-Samkari, H.; Carraway, H. E.; DeZern, A. E.; Mittelman, M.; Little, M.; Beynon, V.; Dai, X.; Sommakia, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • First results of asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors for patients with chronic myeloid leukemia who do not achieve a deep molecular remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)
    Meeting Abstract

    Cortes, J. E.; Mauro, M. J.; Visotcky, A.; Tantravahi, S. K.; Thompson, J. E.; Yang, J.; Baim, A.; Gao, Y.; Maldonado-Schmidt, S.; Olig, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Derkach, A.; Zeidan, A. M.; Stein, E. M.; Mauro, M. J.; Podoltsev, N. A.; Rampal, R.
    Blood (2024)

    Fulltext@MSK | Save
  • Cardinal: A phase I, multicenter, open-label, dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TERN-701 in chronic myeloid leukemia
    Meeting Abstract

    Jabbour, E.; Rea, D.; Cortes, J. E.; Hochhaus, A.; Hughes, T. P.; Kim, D. W.; Kantarjian, H. M.; Holes, L.; Kuriakose, E. T.; Mauro, M. J.
    Blood (2024)

    Fulltext@MSK | Save
  • Two decade single institution experience highlights rare survivors with relapsed or refractory Burkitt lymphoma
    Meeting Abstract

    Molla, R.; Berman, E.; Caron, P.; Donnelly, G.; Falchi, L.; Hamlin, P. A.; Horwitz, S.; Intlekofer, A. M.; Johnson, W. T.; Jurcic, J. G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available CDC-like Kinase inhibitor, BH-30236, in adults with R/R AML or HR-MDS
    Meeting Abstract

    Stein, E. M.; Boussi, L.; Mims, A.; Watts, J. M.; Mannis, G. N.; Liu, H.; Sallman, D.; Ravandi, F.; Schiller, G. J.; Wang, E. S.; more...
    Blood (2024)

    Fulltext@MSK | Save